Sunhee Ro

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

José Baselga, J. G. M. Segalla, Henri Roché et al. · Journal of Clinical Oncology · 2012 · 163 citations · Full text

Medicine, Oncology, Pharmacology +15

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

William J. Gradishar, Virginia Kaklamani, Tarini Prasad Sahoo et al. · European Journal of Cancer · 2012 · 86 citations

Medicine, Oncology, Pharmacology +12

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Lee S. Schwartzberg, Kurt W. Tauer, Robert C. Hermann et al. · Clinical Cancer Research · 2013 · 70 citations · Full text

Medicine, Oncology, Pharmacology +17